TIDMSLN
RNS Number : 1618P
Silence Therapeutics PLC
15 October 2021
Silence Therapeutics and Hansoh Pharma Announce Collaboration to
Develop Therapeutics Leveraging Silence's mRNAi GOLD(TM)
Platform
Hansoh will make a $16 million upfront cash payment and Silence
has the potential to receive up to $1.3 billion in milestones
Silence gains exclusive rights to two targets in all territories
except the China region; Hansoh has rights to those two targets in
the China region and global rights to a third target
15 October 2021
LONDON and SHANGHAI, Silence Therapeutics plc (AIM: SLN and
Nasdaq: SLN ), a leader in the discovery, development and delivery
of novel short interfering ribonucleic acid (siRNA) therapeutics
for the treatment of diseases with significant unmet medical need,
and Hansoh Pharmaceutical Group Company Limited ("Hansoh Pharma",
3692.HK), one of the leading biopharmaceutical companies in China,
today announced a collaboration to develop siRNAs for three
undisclosed targets leveraging Silence's proprietary mRNAi GOLD(TM)
platform.
Under the terms of the agreement, Hansoh will have the exclusive
option to license rights to the first two targets in Greater China,
Hong Kong, Macau and Taiwan following the completion of phase 1
studies. Silence will retain exclusive rights for those two targets
in all other territories. Silence will be responsible for all
activities up to option exercise and will retain responsibility for
development outside the China region post phase 1 studies.
Hansoh will also have the exclusive option to license global
rights to a third target at the point of IND filing. Hansoh will be
responsible for all development activities post option exercise for
the third target.
Hansoh will make a $16 million upfront payment and Silence is
eligible to receive up to $1.3 billion in additional development,
regulatory and commercial milestones. Silence will also receive
royalties tiered from low double-digit to mid-teens on Hansoh net
product sales.
Mark Rothera, President and Chief Executive Officer of Silence
Therapeutics, said: "We believe Hansoh's extensive clinical
development and commercialization experience in China make them an
ideal partner. This collaboration is a good example of our hybrid
model in action, balancing proprietary and partnered programs to
maximize the substantial opportunity of our mRNAi GOLD(TM) platform
for targeting disease associated genes in the liver. The Hansoh
partnership enables us to move two new proprietary programs forward
subsidized by non-dilutive capital while also gaining access to the
second largest pharmaceutical market globally. We look forward to
discussing this deal and our broader pipeline in more detail at our
upcoming R&D Day on October 21(st) in New York City."
Eliza Sun, Executive Director of the Board of Hansoh Pharma,
said: "We are excited to partner with Silence, a pioneer in siRNA
therapeutic development with decades of scientific and technical
experience. As one of the largest biopharma in China, Hansoh
strives to partner with innovative companies globally to build out
and advance our robust pipeline spanning across multiple
therapeutic areas. We see substantial opportunity in Silence's
mRNAi GOLD(TM) platform to develop and bring better precision-based
medicines to patients across China and worldwide."
Enquiries:
Silence Therapeutics plc Tel: +1 (646) 637-3208
Gem Hopkins, Head of IR and Corporate Communications
ir@silence-therapeutics.com
Investec Bank plc (Nominated Adviser and Tel: +44 (0) 20
Broker) 7597 5970
Daniel Adams/Gary Clarence
European PR Tel: +44 (0) 20
Consilium Strategic Communications 3709 5700
Mary-Jane Elliott/Chris Welsh/Angela Gray
silencetherapeutics@consilium-comms.com
Hansoh Pharma
Dr. Sophia Dong, Director of Investor Relations
IR@hspharm.com
About Hansoh Pharma
Hansoh Pharma (3692.HK), one of the largest biopharmaceutical
companies in Greater China and in Asia, is committed to discovering
and developing life-changing medicines to help patients conquer
serious diseases and disorders. Hansoh Pharma is supported by over
12,000 dedicated employees in China and the United States. Founded
in 1995, Hansoh has fully integrated research and development,
manufacturing, and commercial capabilities, supporting leading
positions across a broad range of therapeutic areas, including
oncology, central nervous system (CNS) disorders, infectious
diseases, cardiovascular disease, diabetes, and autoimmune
diseases. With the support of over 1,600 highly skilled R&D
professionals, Hansoh has successfully developed multiple
internally discovered drug candidates into NMPA-approved innovative
medicines, including aumolertinib ( (R)), a third-generation EGFR
inhibitor for the treatment of NSCLC with EGFR mutations,
flumatinib ( (R)), a second-generation BCR-ABL inhibitor for
frontline treatment of chronic myeloid leukemia (CML),
PEG-loxenatide ( (R)), the first once-weekly long-acting GLP-1
analogue discovered and developed in China for the treatment of
diabetes, morinidazole ( (R)), a third-generation nitroimidazole
antibiotic and tenofovir amibufenamide ( (R)), the first
second-generation oral anti-HBV drug developed in China. For more
information, please visit www.hspharm.com.
About Silence Therapeutics
Silence Therapeutics is developing a new generation of medicines
by harnessing the body's natural mechanism of RNA interference, or
RNAi, to inhibit the expression of specific target genes thought to
play a role in the pathology of diseases with significant unmet
need. Silence's proprietary mRNAi GOLD(TM) platform can be used to
create siRNAs (short interfering RNAs) that precisely target and
silence disease-associated genes in the liver, which represents a
substantial opportunity. Silence's wholly owned product candidates
include SLN360 designed to address the high and prevalent unmet
medical need in reducing cardiovascular risk in people born with
high levels of lipoprotein(a) and SLN124 designed to address
iron-loading anemia conditions. Silence also maintains ongoing
research and development collaborations with AstraZeneca,
Mallinckrodt Pharmaceuticals, and Takeda, among others. For more
information, please visit
https://www.silence-therapeutics.com/.
Forward-Looking Statements
Certain statements made in this announcement are forward-looking
statements within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995 and other securities laws, including
with respect to the Company's clinical and commercial prospects and
the anticipated timing of data reports from the Company's clinical
trials. These forward-looking statements are not historical facts
but rather are based on the Company's current expectations,
estimates, and projections about its industry; its beliefs; and
assumptions. Words such as 'anticipates,' 'expects,' 'intends,'
'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions
are intended to identify forward-looking statements. These
statements are not guarantees of future performance and are subject
to known and unknown risks, uncertainties, and other factors, some
of which are beyond the Company's control, are difficult to
predict, and could cause actual results to differ materially from
those expressed or forecasted in the forward-looking statements,
including those risks identified in the Company's most recent
Admission Document and its amended Annual Report on Form 20-F filed
with the U.S. Securities and Exchange Commission on April 29, 2021.
The Company cautions security holders and prospective security
holders not to place undue reliance on these forward-looking
statements, which reflect the view of the Company only as of the
date of this announcement. The forward-looking statements made in
this announcement relate only to events as of the date on which the
statements are made. The Company will not undertake any obligation
to release publicly any revisions or updates to these
forward-looking statements to reflect events, circumstances, or
unanticipated events occurring after the date of this announcement
except as required by law or by any appropriate regulatory
authority.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
AGRGPGWUUUPGGRC
(END) Dow Jones Newswires
October 15, 2021 02:00 ET (06:00 GMT)
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Dec 2024 to Jan 2025
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Jan 2024 to Jan 2025
